The survival outcomes and river plot with or without gilteritinib maintenance therapy. (A) OS from transplantation (3-year OS; 85.7% [95% CI, 69.2-100.0] in the gil group vs 27.3% [95% CI, 10.4-71.6] in the nongil group; P =.008). (B) RFS from transplantation (3-year OS; 85.7% [95% CI, 69.2-100.0] in the gil group vs 27.3% [95% CI, 10.4-71.6] in the nongil group; P =.006). (C) CIR from transplantation (3-year CIR; 7.1% [95% CI, 0.0-19.7] in the gil group vs 51.5% [95% CI, 5.1-75.2] in the nongil group; P = .012). (D) Grade 2 to 4 acute GVHD (6-month grade 2-4 acute GVHD; 21.4% [95% CI, 0.0-40.2] in the gil group vs 27.3% [95% CI, 0.0-49.4] in the nongil group; P = .31). (E) Moderate-to-severe chronic GVHD (2-year moderate-to-severe chronic GVHD; 38.9% [95% CI, 4.8-60.8] in the gil group vs 0% [95% CI, 0-0] in the nongil group; P = .12). (F) GRFS from transplantation (3-year GRFS; 50% [95% CI, 29.6-84.4] in the gil group vs 27.3% [95% CI, 10.4-71.6] in the nongil group; P = .076). (G) The river plot is shown. The top river is the gil group, whereas the bottom river is the nongil group. CIR, cumulative incidence of relapse; GRFS, GVHD-free, relapse-free survival; OS, overall survival.